Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eylea for DME with good visual acuity (Protocol V)
NCT01909791Phase 3Completed
- Sponsor
- Jaeb Center for Health Research
- Start
- Oct 2013
- Primary completion
- Sep 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 3 trial of aflibercept in diabetic macular edema (DME), sponsored by Jaeb Center for Health Research. Started Oct 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01909791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01909791.